<code id='07FAE86FC9'></code><style id='07FAE86FC9'></style>
    • <acronym id='07FAE86FC9'></acronym>
      <center id='07FAE86FC9'><center id='07FAE86FC9'><tfoot id='07FAE86FC9'></tfoot></center><abbr id='07FAE86FC9'><dir id='07FAE86FC9'><tfoot id='07FAE86FC9'></tfoot><noframes id='07FAE86FC9'>

    • <optgroup id='07FAE86FC9'><strike id='07FAE86FC9'><sup id='07FAE86FC9'></sup></strike><code id='07FAE86FC9'></code></optgroup>
        1. <b id='07FAE86FC9'><label id='07FAE86FC9'><select id='07FAE86FC9'><dt id='07FAE86FC9'><span id='07FAE86FC9'></span></dt></select></label></b><u id='07FAE86FC9'></u>
          <i id='07FAE86FC9'><strike id='07FAE86FC9'><tt id='07FAE86FC9'><pre id='07FAE86FC9'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:8263
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Xenotransplantation trials will require adjusting expectations, experts say
          Xenotransplantation trials will require adjusting expectations, experts say

          RobertMontgomeryofNewYorkUniversityspeaksasMeganSykesofColumbiaUniversityandInsooHyunofHarvardMedica

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

          JustinSullivan/GettyImagesWhenpeoplemisrepresentfactsontherecord,journalistsareinatoughspot—especial